Philogen licenses autoimmune disease drug to Pfizer

01/4/2013 | Reuters

Pfizer secured exclusive, worldwide rights to develop and market Philogen's Dekavil, an investigational drug for autoimmune diseases. Dekavil is an early-stage antibody that targets inflammatory disease sites. The deal entitles Philogen to an an upfront fee and potential milestone fees and royalties.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC